Halozyme Therapeutics, Inc. (HALO)

Market Cap	12.28B +47.6%
Revenue (ttm)	1.66B +41.2%
Net Income	413.60M -25.8%
EPS	3.38 -22.5%
Shares Out	113.50M
PE Ratio	31.98
Forward PE	11.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,173,961
Open	106.20
Previous Close	106.12
Day's Range	105.91 - 108.49
52-Week Range	61.23 - 108.49
Beta	0.85
Analysts	Buy
Price Target	99.56 (-7.96%)
Earnings Date	Aug 6, 2026

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.

Analyst Summary

According to 9 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $99.56, which is a decrease of -7.96% from the latest price.

Price Target

$99.56

(-7.96% downside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 22, 2026

Data Sources Report a data error